PIERSIGILLI, Fiammetta; AURITI, Cinzia; HAYWOOD LOMBARDI, Mary; PRENCIPE, Giusi; CAMPI, Francesca; DOTTA, Andrea
October 2013
Pedijatrija Danas: Pediatrics Today;Oct2013, Vol. 9 Issue 2, p170
Academic Journal
Objectives -- To investigate the dose of enoxaparin required in neo-nates to achieve target therapeutic ranges of anti factor Xa 48 hours after starting therapy, and compare this dose to recommended guideline dosages for neonates. Methods -- We retrospectively reviewed 19 records of newborns who received enoxaparin at different doses for the treatment of thrombosis and evaluated how many among them reached the target anti-factor Xa level after 48 hours. Results -- Only 1/5 neonates (20%) treated with 150 UI/kg twice a day, but 100% (6/6) of those treated with 175 UI/kg twice a day reached therapeutic levels of anti-factor Xa at 48 hours. Of the 8 neonates treated with lower starting doses none reached the therapeutic range after 48 hours and these required the highest number of dose changes. Conclusions -- Our results reinforce the need to increase in neonates the dosage of enoxaparin suggested in published guidelines, in order to shorten the time-delay in achieving a therapeutic level of anti-factor Xa, and also reducing the number of blood tests necessary for dosing anti-factor Xa.


Related Articles

  • Trombosis de la arteria renal en un recién nacido. Presentación de un caso y revisión. Torres, Ana Lucía; Torres, Javier; Cifuentes, Jorge Andrés // Colombia Medica;ene-mar2009, Vol. 40 Issue 1, p114 

    This report describes a newborn who presents high pressure values and absence of pulses in inferior extremities in his 4th day of life. Posterior to placement of umbilical arterial catheter, confirming diagnostic of thrombosis in aorta and left renal artery. A gamagraphy with MAG 3 was performed...

  • Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays. Thomas, Owain; Lybeck, Emanuel; Strandberg, Karin; Tynngård, Nahreen; Schött, Ulf // PLoS ONE;Jan2015, Vol. 10 Issue 1, p1 

    Background: Low molecular weight heparins (LMWH’s) are used to prevent and treat thrombosis. Tests for monitoring LMWH’s include anti-factor Xa (anti-FXa), activated partial thromboplastin time (aPTT) and thrombin generation. Anti-FXa is the current gold standard despite...

  • Hematoma of Rectus Sheath Following Subcutaneous Enoxaparin Injection. Firoozbakhsh, Shahram; Parsaei, Reza; Jafarshad, Reyhaneh // Acta Medica Iranica;2013, Vol. 51 Issue 5, p334 

    Anticoagulation drugs are frequently used to prevent deep vein thrombosis in high-risk patients. Subcutaneous low molecular weight heparin (LMWH) is increasingly used in both hospitalized patients and outpatient settings. This necessitates familiarity of both health care providers and patients...

  • Argatroban. McKeage, K.; Plosker, G.L. // Drugs;Feb2001, Vol. 61 Issue 4, p515 

    â–´ Argatroban is a direct thrombin inhibitor synthesised to bind to the catalytic site of the thrombin molecule. It binds rapidly and reversibly to both clot-bound and soluble thrombin. â–´ The relatively short elimination half-life of argatroban (39 to 51 minutes) and its reversible...

  • 153-13. DVT AND LUPUS ANTIBODIES.  // Cortlandt Forum;11/25/2000, Vol. 13 Issue 11, p88 

    Discusses treatment for a patient with deep vein thrombosis (DVT) in both legs. Risks involved in treating the patient with lupus anticoagulant and anticardiolipin antibodies; Need for the patient to be anticoagulated indefinitely if low-molecular-weight heparin will be given.

  • Enoxaparin sodium.  // Reactions Weekly;6/8/2013, Issue 1456, p17 

    The article presents a case study of a 61-year-old woman who developed a suprachoroidal haemorrhage after taking enoxaparin sodium.

  • Enoxaparin sodium.  // Reactions Weekly;Jun2015, Vol. 1557 Issue 1, p91 

    The article presents a case study of a 53-year-old female patient who developed type II heparin induced thrombocytopenia with subsequent thromboembolic events after being treated with enoxaparin sodium.

  • Cerebral venous sinus thrombosis in children with nephrotic syndrome. Gera, D.N.; Yadav, D.K.; Kute, V.B.; Patil, S.B.; Trivedi, H.L. // Indian Journal of Nephrology;Nov/Dec2012, Vol. 22 Issue 6, p455 

    Nephrotic syndrome in infancy and childhood can be associated with thromboembolic complications. We describe two cases of nephrotic syndrome who presented with non-specific findings. Magnetic resonance imaging brain with magnetic resonance venography showed thrombosis of multiple venous sinuses....

  • Enoxaparin sodium.  // Reactions Weekly;Aug2014, Vol. 1515 Issue 1, p87 

    The article presents a case study on the 51-year-old man experienced an anaphylactoid reaction following treatment with enoxaparin sodium.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics